Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| VERACYTE, INC.VCYT · Entity 2018 | Chief Scientific & Med Officer | December 06, 2022 | December 08, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
VERACYTE, INC.
Report date December 06, 2022 · Filed December 08, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 65,970 |
Reported balance
After 2022-12-06 transaction · row 1
1 source rowRow 1 · 2022-12-06 · Sale · Disposed 1,023 · Balance 65,970 F1: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 14, 2022. |
Filing footnotes · ownership attribution and instrument terms
F1: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 14, 2022.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 07, 2021 Filed Sep 9, 2021 21:07 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionStock Option (right to buy) · Derivative | 4,406 | $0.00 Strike: $5.98 | $0.00 |
DisclosureSEC source: 0001384101-21-000155 · wf-form4_163122163694896.xml · derivative · entry 7 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,813 Underlying: Common Stock · 4,406 shares Expires 2028-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 11, 2021. F4 · derivative.exercise_date: The option becomes exercisable as to 25% of the shares on March 2, 2019, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter. Read SEC document |
| September 07, 2021 Filed Sep 9, 2021 21:07 UTC | VERACYTE, INC. VCYT · Entity 2018 | SaleCommon Stock | 497 | $51.23 | $25,462.80 |
DisclosureSEC source: 0001384101-21-000155 · wf-form4_163122163694896.xml · nonDerivative · entry 5 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,975 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 11, 2021. F3 · price: Represents weighted average sales price. Sale prices for the transactions range from $51.07 to $51.33. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| September 07, 2021 Filed Sep 9, 2021 21:07 UTC | VERACYTE, INC. VCYT · Entity 2018 | SaleCommon Stock | 12,034 | $50.52 | $607,945.65 |
DisclosureSEC source: 0001384101-21-000155 · wf-form4_163122163694896.xml · nonDerivative · entry 4 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,472 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 11, 2021. F2 · price: Represents weighted average sales price. Sale prices for the transactions range from $50.06 to $51.06. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| September 07, 2021 Filed Sep 9, 2021 21:07 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionCommon Stock | 4,375 | $24.69 | $108,018.75 |
DisclosureSEC source: 0001384101-21-000155 · wf-form4_163122163694896.xml · nonDerivative · entry 3 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,506 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 11, 2021. Read SEC document |
| September 07, 2021 Filed Sep 9, 2021 21:07 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionCommon Stock | 3,750 | $20.21 | $75,787.50 |
DisclosureSEC source: 0001384101-21-000155 · wf-form4_163122163694896.xml · nonDerivative · entry 2 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,131 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 11, 2021. Read SEC document |
| September 07, 2021 Filed Sep 9, 2021 21:07 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionCommon Stock | 4,406 | $5.98 | $26,347.88 |
DisclosureSEC source: 0001384101-21-000155 · wf-form4_163122163694896.xml · nonDerivative · entry 1 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,381 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 11, 2021. Read SEC document |
| September 02, 2021 Filed Sep 7, 2021 21:11 UTC | VERACYTE, INC. VCYT · Entity 2018 | Tax withholdingCommon Stock | 912 | $52.97 | $48,308.64 |
DisclosureSEC source: 0001384101-21-000150 · wf-form4_163104909320686.xml · nonDerivative · entry 1 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,975 F1 · kind: The reporting person is reporting the withholding of 292, 248 and 372 shares of common stock to satisfy the reporting person's tax withholding obligations in connection with the vesting of 588, 500 and 750 Restricted Stock Units, respectively, granted on March 2, 2018, February 28, 2019 and February 28, 2020 respectively, and does not represent a sale by the reporting person. Read SEC document |
| June 23, 2021 Filed Jun 25, 2021 20:12 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionStock Option (right to buy) · Derivative | 4,375 | $0.00 Strike: $24.69 | $0.00 |
DisclosureSEC source: 0001384101-21-000116 · wf-form4_162465194522576.xml · derivative · entry 3 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,125 Underlying: Common Stock · 4,375 shares Expires 2030-03-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 12, 2020. F3 · derivative.exercise_date: The option becomes exercisable as to 25% of the shares on February 28, 2021, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter. Read SEC document |
| June 23, 2021 Filed Jun 25, 2021 20:12 UTC | VERACYTE, INC. VCYT · Entity 2018 | SaleCommon Stock | 4,375 | $39.75 | $173,913.69 |
DisclosureSEC source: 0001384101-21-000116 · wf-form4_162465194522576.xml · nonDerivative · entry 2 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,887 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 12, 2020. F2 · price: Represents weighted average sales price. Sale prices for the transactions range from $39.69 to $39.84. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| June 23, 2021 Filed Jun 25, 2021 20:12 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionCommon Stock | 4,375 | $24.69 | $108,018.75 |
DisclosureSEC source: 0001384101-21-000116 · wf-form4_162465194522576.xml · nonDerivative · entry 1 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,262 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 12, 2020. Read SEC document |
| June 04, 2021 Filed Jun 8, 2021 20:38 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionStock Option (right to buy) · Derivative | 3,750 | $0.00 Strike: $20.21 | $0.00 |
DisclosureSEC source: 0001384101-21-000101 · wf-form4_162318467981821.xml · derivative · entry 7 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,250 Underlying: Common Stock · 3,750 shares Expires 2029-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The option becomes exercisable as to 25% of the shares on February 28, 2020, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter. Read SEC document |
| June 04, 2021 Filed Jun 8, 2021 20:38 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionStock Option (right to buy) · Derivative | 4,406 | $0.00 Strike: $5.98 | $0.00 |
DisclosureSEC source: 0001384101-21-000101 · wf-form4_162318467981821.xml · derivative · entry 6 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,219 Underlying: Common Stock · 4,406 shares Expires 2028-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option becomes exercisable as to 25% of the shares on March 2, 2019, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter Read SEC document |
| June 04, 2021 Filed Jun 8, 2021 20:38 UTC | VERACYTE, INC. VCYT · Entity 2018 | SaleCommon Stock | 4,979 | $35.17 | $175,112.43 |
DisclosureSEC source: 0001384101-21-000101 · wf-form4_162318467981821.xml · nonDerivative · entry 5 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,887 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 12, 2020. F4 · price: Represents weighted average sales price. Sale prices for the transactions range from $34.95 to $35.27. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| June 04, 2021 Filed Jun 8, 2021 20:38 UTC | VERACYTE, INC. VCYT · Entity 2018 | SaleCommon Stock | 2,595 | $34.39 | $89,251.39 |
DisclosureSEC source: 0001384101-21-000101 · wf-form4_162318467981821.xml · nonDerivative · entry 4 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,866 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 12, 2020. F3 · price: Represents weighted average sales price. Sale prices for the transactions range from $33.93 to $34.93. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| June 04, 2021 Filed Jun 8, 2021 20:38 UTC | VERACYTE, INC. VCYT · Entity 2018 | SaleCommon Stock | 1,507 | $33.28 | $50,151.45 |
DisclosureSEC source: 0001384101-21-000101 · wf-form4_162318467981821.xml · nonDerivative · entry 3 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,461 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 12, 2020. F2 · price: Represents weighted average sales price. Sale prices for the transactions range from $32.92 to $33.68. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| June 04, 2021 Filed Jun 8, 2021 20:38 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionCommon Stock | 3,750 | $20.21 | $75,787.50 |
DisclosureSEC source: 0001384101-21-000101 · wf-form4_162318467981821.xml · nonDerivative · entry 2 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,968 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 12, 2020. Read SEC document |
| June 04, 2021 Filed Jun 8, 2021 20:38 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionCommon Stock | 4,406 | $5.98 | $26,347.88 |
DisclosureSEC source: 0001384101-21-000101 · wf-form4_162318467981821.xml · nonDerivative · entry 1 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,218 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 12, 2020. Read SEC document |
| June 02, 2021 Filed Jun 4, 2021 20:56 UTC | VERACYTE, INC. VCYT · Entity 2018 | Tax withholdingCommon Stock | 912 | $36.07 | $32,895.84 |
DisclosureSEC source: 0001384101-21-000096 · wf-form4_162284014712611.xml · nonDerivative · entry 1 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,812 F1 · kind: The reporting person is reporting the withholding of 292, 248 and 372 shares of common stock to satisfy the reporting person's tax withholding obligations in connection with the vesting of 587, 500 and 750 Restricted Stock Units, respectively, granted on March 2, 2018, February 28, 2019 and February 28, 2020 respectively, and does not represent a sale by the reporting person. Read SEC document |
| March 04, 2021 Filed Mar 8, 2021 22:33 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionStock Option (right to buy) · Derivative | 17,500 | $0.00 Strike: $24.69 | $0.00 |
DisclosureSEC source: 0001384101-21-000044 · wf-form4_161524279377824.xml · derivative · entry 17 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,500 Underlying: Common Stock · 17,500 shares Expires 2030-03-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 12, 2020. F14 · derivative.exercise_date: The option becomes exercisable as to 25% of the shares on February 28, 2021, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter. Read SEC document |
| March 04, 2021 Filed Mar 8, 2021 22:33 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionStock Option (right to buy) · Derivative | 3,750 | $0.00 Strike: $20.21 | $0.00 |
DisclosureSEC source: 0001384101-21-000044 · wf-form4_161524279377824.xml · derivative · entry 16 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 3,750 shares Expires 2029-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 12, 2020. F13 · derivative.exercise_date: The option becomes exercisable as to 25% of the shares on February 28, 2020, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter. Read SEC document |
| March 04, 2021 Filed Mar 8, 2021 22:33 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionStock Option (right to buy) · Derivative | 4,407 | $0.00 Strike: $5.98 | $0.00 |
DisclosureSEC source: 0001384101-21-000044 · wf-form4_161524279377824.xml · derivative · entry 15 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,625 Underlying: Common Stock · 4,407 shares Expires 2028-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 12, 2020. F12 · derivative.exercise_date: The option becomes exercisable as to 25% of the shares on March 2, 2019, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter. Read SEC document |
| March 04, 2021 Filed Mar 8, 2021 22:33 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionStock Option (right to buy) · Derivative | 5,313 | $0.00 Strike: $9.05 | $0.00 |
DisclosureSEC source: 0001384101-21-000044 · wf-form4_161524279377824.xml · derivative · entry 14 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,313 shares Expires 2027-03-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 12, 2020. F11 · derivative.exercise_date: The option is fully vested. Read SEC document |
| March 04, 2021 Filed Mar 8, 2021 22:33 UTC | VERACYTE, INC. VCYT · Entity 2018 | SaleCommon Stock | 300 | $55.49 | $16,647.00 |
DisclosureSEC source: 0001384101-21-000044 · wf-form4_161524279377824.xml · nonDerivative · entry 13 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,724 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 12, 2020. F10 · price: Represents weighted average sales price. Sale prices for the transactions range from $55.31 to $55.67. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| March 04, 2021 Filed Mar 8, 2021 22:33 UTC | VERACYTE, INC. VCYT · Entity 2018 | SaleCommon Stock | 1,431 | $54.72 | $78,310.04 |
DisclosureSEC source: 0001384101-21-000044 · wf-form4_161524279377824.xml · nonDerivative · entry 12 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,024 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 12, 2020. F9 · price: Represents weighted average sales price. Sale prices for the transactions range from $54.11 to $55.10. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| March 04, 2021 Filed Mar 8, 2021 22:33 UTC | VERACYTE, INC. VCYT · Entity 2018 | SaleCommon Stock | 2,606 | $53.50 | $139,414.49 |
DisclosureSEC source: 0001384101-21-000044 · wf-form4_161524279377824.xml · nonDerivative · entry 11 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,455 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 12, 2020. F8 · price: Represents weighted average sales price. Sale prices for the transactions range from $52.99 to $53.99. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| March 04, 2021 Filed Mar 8, 2021 22:33 UTC | VERACYTE, INC. VCYT · Entity 2018 | SaleCommon Stock | 5,032 | $52.38 | $263,564.08 |
DisclosureSEC source: 0001384101-21-000044 · wf-form4_161524279377824.xml · nonDerivative · entry 10 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,061 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 12, 2020. F7 · price: Represents weighted average sales price. Sale prices for the transactions range from $51.94 to $52.93. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| March 04, 2021 Filed Mar 8, 2021 22:33 UTC | VERACYTE, INC. VCYT · Entity 2018 | SaleCommon Stock | 8,114 | $51.38 | $416,900.57 |
DisclosureSEC source: 0001384101-21-000044 · wf-form4_161524279377824.xml · nonDerivative · entry 9 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,093 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 12, 2020. F6 · price: Represents weighted average sales price. Sale prices for the transactions range from $50.90 to $51.89. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| March 04, 2021 Filed Mar 8, 2021 22:33 UTC | VERACYTE, INC. VCYT · Entity 2018 | SaleCommon Stock | 2,819 | $50.40 | $142,073.37 |
DisclosureSEC source: 0001384101-21-000044 · wf-form4_161524279377824.xml · nonDerivative · entry 8 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,207 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 12, 2020. F5 · price: Represents weighted average sales price. Sale prices for the transactions range from $49.87 to $50.87. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| March 04, 2021 Filed Mar 8, 2021 22:33 UTC | VERACYTE, INC. VCYT · Entity 2018 | SaleCommon Stock | 2,991 | $49.22 | $147,209.84 |
DisclosureSEC source: 0001384101-21-000044 · wf-form4_161524279377824.xml · nonDerivative · entry 7 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,026 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 12, 2020. F4 · price: Represents weighted average sales price. Sale prices for the transactions range from $48.82 to $49.81. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| March 04, 2021 Filed Mar 8, 2021 22:33 UTC | VERACYTE, INC. VCYT · Entity 2018 | SaleCommon Stock | 8,483 | $48.29 | $409,607.59 |
DisclosureSEC source: 0001384101-21-000044 · wf-form4_161524279377824.xml · nonDerivative · entry 6 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,017 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 12, 2020. F3 · price: Represents weighted average sales price. Sale prices for the transactions range from $47.80 to $48.80. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| March 04, 2021 Filed Mar 8, 2021 22:33 UTC | VERACYTE, INC. VCYT · Entity 2018 | SaleCommon Stock | 20,239 | $47.11 | $953,544.29 |
DisclosureSEC source: 0001384101-21-000044 · wf-form4_161524279377824.xml · nonDerivative · entry 5 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,500 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 12, 2020. F2 · price: Represents weighted average sales price. Sale prices for the transactions range from $46.78 to $47.78. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| March 04, 2021 Filed Mar 8, 2021 22:33 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionCommon Stock | 17,500 | $24.69 | $432,075.00 |
DisclosureSEC source: 0001384101-21-000044 · wf-form4_161524279377824.xml · nonDerivative · entry 4 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,739 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 12, 2020. Read SEC document |
| March 04, 2021 Filed Mar 8, 2021 22:33 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionCommon Stock | 3,750 | $20.21 | $75,787.50 |
DisclosureSEC source: 0001384101-21-000044 · wf-form4_161524279377824.xml · nonDerivative · entry 3 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,239 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 12, 2020. Read SEC document |
| March 04, 2021 Filed Mar 8, 2021 22:33 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionCommon Stock | 4,407 | $5.98 | $26,353.86 |
DisclosureSEC source: 0001384101-21-000044 · wf-form4_161524279377824.xml · nonDerivative · entry 2 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,489 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 12, 2020. Read SEC document |
| March 04, 2021 Filed Mar 8, 2021 22:33 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionCommon Stock | 5,313 | $9.05 | $48,082.65 |
DisclosureSEC source: 0001384101-21-000044 · wf-form4_161524279377824.xml · nonDerivative · entry 1 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,082 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 12, 2020. Read SEC document |
| March 02, 2021 Filed Mar 4, 2021 22:05 UTC | VERACYTE, INC. VCYT · Entity 2018 | Tax withholdingCommon Stock | 5,995 | $62.15 | $372,589.25 |
DisclosureSEC source: 0001384101-21-000038 · wf-form4_161489554524867.xml · nonDerivative · entry 1 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,769 F1 · kind: The reporting person is reporting the withholding of 292, 248, 3,967 and 1,488 shares of common stock to satisfy the reporting person's tax withholding obligations in connection with the vesting of 588, 500, 8,000 and 3,000 Restricted Stock Units, respectively, granted on March 2, 2018, February 28, 2019, February 28, 2019 and February 28, 2020 respectively, and does not represent a saleby the reporting person. Read SEC document |
| February 26, 2021 Filed Mar 2, 2021 22:19 UTC | VERACYTE, INC. VCYT · Entity 2018 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $58.06 | $0.00 |
DisclosureSEC source: 0001384101-21-000028 · wf-form4_161472354334446.xml · derivative · entry 2 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2031-02-26 F2 · derivative.exercise_date: The option becomes exercisable as to 25% of the shares on February 26, 2022, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter. Read SEC document |
| February 26, 2021 Filed Mar 2, 2021 22:19 UTC | VERACYTE, INC. VCYT · Entity 2018 | GrantCommon Stock | 12,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001384101-21-000028 · wf-form4_161472354334446.xml · nonDerivative · entry 1 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,764 F1 · kind: Restricted stock units awarded on February 26, 2021 vest 25% on March 2, 2022 and 1/16 per quarter thereafter subject to continuing employment of the Reporting Person on each vesting date. Read SEC document |
| February 24, 2021 Filed Feb 26, 2021 21:41 UTC | VERACYTE, INC. VCYT · Entity 2018 | Tax withholdingCommon Stock | 10,048 | $62.30 | $625,990.40 |
DisclosureSEC source: 0001384101-21-000020 · wf-form4_161437563530725.xml · nonDerivative · entry 1 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,264 F1 · shares: The reporting person is reporting the withholding of 10,048 shares of common stock to satisfy the reporting person's tax withholding obligations in connection with the vesting of 25,000 Performance Stock Units vested on February 24, 2021 and does not represent a sale by the reporting person. Read SEC document |
| December 04, 2020 Filed Dec 5, 2020 00:42 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionStock Option (right to buy) · Derivative | 3,750 | $0.00 Strike: $20.21 | $0.00 |
DisclosureSEC source: 0001437749-20-024903 · rdgdoc.xml · derivative · entry 10 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,750 Underlying: Common Stock · 3,750 shares Expires 2029-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 12, 2020. F8 · derivative.exercise_date: The option becomes exercisable as to 25% of the shares on February 28, 2020, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter. Read SEC document |
| December 04, 2020 Filed Dec 5, 2020 00:42 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionStock Option (right to buy) · Derivative | 4,406 | $0.00 Strike: $5.98 | $0.00 |
DisclosureSEC source: 0001437749-20-024903 · rdgdoc.xml · derivative · entry 9 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,032 Underlying: Common Stock · 4,406 shares Expires 2028-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 12, 2020. F7 · derivative.exercise_date: The option becomes exercisable as to 25% of the shares on March 2, 2019, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter. Read SEC document |
| December 04, 2020 Filed Dec 5, 2020 00:42 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionStock Option (right to buy) · Derivative | 5,312 | $0.00 Strike: $9.05 | $0.00 |
DisclosureSEC source: 0001437749-20-024903 · rdgdoc.xml · derivative · entry 8 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,313 Underlying: Common Stock · 5,312 shares Expires 2027-03-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 12, 2020. F6 · derivative.exercise_date: The option becomes exercisable as to 25% of the shares on March 3, 2018, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter. Read SEC document |
| December 04, 2020 Filed Dec 5, 2020 00:42 UTC | VERACYTE, INC. VCYT · Entity 2018 | SaleCommon Stock | 6,094 | $57.55 | $350,731.64 |
DisclosureSEC source: 0001437749-20-024903 · rdgdoc.xml · nonDerivative · entry 7 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,312 F2 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 12, 2020. F5 · price: Represents weighted average sales price. Sale prices for the transactions range from $57.31 to $57.90. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| December 04, 2020 Filed Dec 5, 2020 00:42 UTC | VERACYTE, INC. VCYT · Entity 2018 | SaleCommon Stock | 4,279 | $56.86 | $243,284.68 |
DisclosureSEC source: 0001437749-20-024903 · rdgdoc.xml · nonDerivative · entry 6 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,406 F2 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 12, 2020. F4 · price: Represents weighted average sales price. Sale prices for the transactions range from $56.28 to $57.11. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| December 04, 2020 Filed Dec 5, 2020 00:42 UTC | VERACYTE, INC. VCYT · Entity 2018 | SaleCommon Stock | 3,642 | $55.78 | $203,139.83 |
DisclosureSEC source: 0001437749-20-024903 · rdgdoc.xml · nonDerivative · entry 5 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,685 F2 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 12, 2020. F3 · price: Represents weighted average sales price. Sale prices for the transactions range from $55.27 to $56.13. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| December 04, 2020 Filed Dec 5, 2020 00:42 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionCommon Stock | 3,750 | $20.21 | $75,787.50 |
DisclosureSEC source: 0001437749-20-024903 · rdgdoc.xml · nonDerivative · entry 4 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,327 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 12, 2020. Read SEC document |
| December 04, 2020 Filed Dec 5, 2020 00:42 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionCommon Stock | 4,406 | $5.98 | $26,347.88 |
DisclosureSEC source: 0001437749-20-024903 · rdgdoc.xml · nonDerivative · entry 3 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,577 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 12, 2020. Read SEC document |
| December 04, 2020 Filed Dec 5, 2020 00:42 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionCommon Stock | 5,312 | $9.05 | $48,073.60 |
DisclosureSEC source: 0001437749-20-024903 · rdgdoc.xml · nonDerivative · entry 2 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,171 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 12, 2020. Read SEC document |
| December 02, 2020 Filed Dec 5, 2020 00:42 UTC | VERACYTE, INC. VCYT · Entity 2018 | Tax withholdingCommon Stock | 540 | $55.08 | $29,743.20 |
DisclosureSEC source: 0001437749-20-024903 · rdgdoc.xml · nonDerivative · entry 1 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,859 F1 · kind: The reporting person is reporting the withholding of 292 and 248 shares of common stock to satisfy the reporting person's tax withholding obligations in connection with the vesting of 587 and 500 Restricted Stock Units, respectively granted on March 2, 2018 and February 28, 2019, respectively, and does not represent a sale by the reporting person. Read SEC document |
| October 06, 2020 Filed Oct 7, 2020 21:06 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionStock Option (right to buy) · Derivative | 2,500 | $0.00 Strike: $20.21 | $0.00 |
DisclosureSEC source: 0001437749-20-020855 · rdgdoc.xml · derivative · entry 3 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,500 Underlying: Common Stock · 2,500 shares Expires 2029-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 12, 2020. F2 · derivative.exercise_date: The option becomes exercisable as to 25% of the shares on February 28, 2020, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.